Quick Take: Why Pharma Can’t Copy-Paste Automation from Detroit

Walk into a modern car plant, and you’ll see a symphony of synchronized robots—welding, painting, assembling with metronomic precision. Walk into a pharmaceutical facility, and you’ll see… a lot of humans in white coats, pipetting, inspecting vials, and filling out paperwork. The contrast is striking. And it raises an obvious question: if automakers have been automating for decades, why can’t pharma just do the same?

The short answer: because a batch of pills is not a car door.

In automotive manufacturing, the goal is consistency at scale. Every door on every car rolling off the line should be identical—or close enough that no one notices. Automation thrives on that kind of predictability. Parts move down a fixed conveyor, robots perform the same operation thousands of times a day, and deviations are caught and corrected quickly. If a weld is slightly off, you scrap the part and move on. The cost of failure is measured in dollars and minutes.

Pharma doesn’t have that luxury. When you’re manufacturing a biologic or a cell therapy, you can’t fully characterize the molecule—let alone replicate it with the same certainty as a stamped metal panel. Biological systems are inherently variable. Patient-derived cells arrive at unpredictable times; growth rates fluctuate from one batch to the next. You can’t just “test the finished product” and call it done, because by the time you know something went wrong, you may have already compromised an irreplaceable patient-specific batch. Quality control has to happen at every step, not just at the end of the line.

Then there’s the regulatory elephant in the room. In pharma, every change—every tweak to a process, every new piece of software—triggers a validation nightmare. Manual processes, despite their variability and operator dependence, are often accepted as the default. Automation, by contrast, is treated as a change that requires additional justification. The burden of proof falls on those trying to reduce variability, not on those maintaining it. In the EU, draft GMP Annex 22 currently only permits static, deterministic models in GMP-critical applications—dynamic AI and generative models are explicitly excluded. The FDA made its position equally clear in April 2026, issuing a warning letter after a firm used AI agents to generate GMP documents without qualified human review. The message: AI can inform and recommend, but it cannot own accountability.

The skills gap doesn’t help either. Eight in ten pharmaceutical manufacturers report a mismatch between what their workforce can do and what digital production now demands. The industry doesn’t need more data scientists—it needs people who can sit at the intersection of regulated manufacturing and algorithmic decision support. Those hybrids are in painfully short supply.

And perhaps the most counterintuitive barrier: pharma keeps automating the wrong thing. One industry leader recently diagnosed the problem bluntly: organizations keep layering technology on top of broken processes instead of fixing the foundation first. The result? More overhead, more pseudo-work, and the same old problems—just digitized.

So no, pharma can’t automate like everyone else. Not because the technology isn’t there—it is. But because the stakes are higher, the biology is messier, the regulators are stricter, and the processes are often broken before you even start. The automotive industry mastered the art of making identical things, identically, every time. Pharma’s job is infinitely harder: making things that are almost identical, almost every time, while knowing that “almost” isn’t good enough when a patient’s life is on the line.

That’s not a problem you solve with more robots. That’s a problem you solve by rethinking everything—from the process up. And that takes time, talent, and a regulatory system willing to evolve alongside the technology. The car plants figured it out decades ago. Pharma is still figuring it out—one batch, one validation, one hard-won regulatory approval at a time.